The round was led by Growth Equity at Goldman Sachs Alternatives and values the company at $1.1bn.
"By connecting people to the AI, data, and systems they need to do their best work, the opportunity before us at Tines is to become the universal orchestrator of modern, secure workflows across the enterprise. This new round will help us realise that opportunity."
The oversubscribed round was led by Lakestar with participation from Perpetual Growth, CF Private Equity, Bessemer Venture Partners, and 83North.
"After spending two years perfecting our SaaS and cloud spend optimisation, achieving product-market fit and taking market share from established players, we’ve brought all of our data and insights directly into the workflow experience. All employees can now initiate any purchase, quickly, transparently and at the best price, while procurement can fully customise the workflows to their needs and embed granular approvals."
The Series C round was led by Highland Europe with participation from ETFS Capital to support product development and team expansion.
"Financial advice is a heavily regulated space and it is difficult for fintech platforms to break through unless they truly understand how to manage and enable operations for their customers. For the past six years, we have been building Fundment as the all-in-one tech platform to support a financial advice firm’s every need so they can dedicate more time to delivering value to customers. We now have over 500 firms relying on Fundment, but we’re still in the early stages of our journey. I’m delighted to have the backing of Highland Europe and look forward to working with the knowledgeable team there as we scale Fundment."
The Dublin-based artificial intelligence startup secured backing from Molten Ventures, ACT Venture Capital, and Seroba to expand its global footprint.
"This investment accelerates our mission to transform global pathology access. Our ergonomic, AI-enabled platform enhances diagnostic workflow and accuracy – allowing experts to clear backlogs faster without compromising quality. By expanding this technology worldwide, we’re not just improving healthcare efficiency, we’re supporting both the pathologists who drive diagnoses and the patients who depend on them."